Search Grants — Free, No Account Required

NIMH - National Institute of Mental Health

Project Summary Schizophrenia (SCZ) is a severe psychiatric disorder with a complex genetic component. Genetic studies have identified a strong link between genetic risk and the neurodevelopmental processes of the brain, contributing to SCZ etiology. Notably, neurogenesis is especially vulnerable to disruption by SCZ genetic factors. However, which SCZ-associated risk genes and variants affect neurogenesis and how non-coding risk variants influence risk gene expression remains largely unknown. The overarching goal of this K99/R00 project is to systematically delineate the direct connection among SCZ-associated variants, risk genes, and neurogenesis by developing and applying advanced functional genomic screening platforms in cerebral organoids. During the K99 phase, I will elucidate the roles of SCZ risk genes in neurogenesis by conducting pooled high throughput CRISPR interference screens in key neurogenic cell types derived from cerebral organoids. During the K99/R00 phase, I will employ prime editing screens in cerebral organoids to assess the effects of individual SCZ-associated variants on neurogenesis. Finally, during the R00 phase, I will investigate the regulatory impact of non-coding SCZ variants on gene expression using single-cell prime editing screens in cerebral organoids. The successful completion of these aims will provide novel insights into which and how SCZ-associated genes and variants disrupt neurogenesis, advancing our understanding of the neurodevelopmental basis of SCZ and aiding in identifying novel therapeutic targets. Additionally, this research will enhance our ability to interpret the broader role of genetic factors in neurogenesis and will generate essential training data for machine learning models focused on neurogenesis, with potential implications for other neurodevelopmental disorders. During the K99 phase, I will further improve my expertise in functional genomics, organoid models, statistical analysis, machine learning, and neurobiology of SCZ, as well as other essential professional skills, including leadership, mentoring, writing, and presentation. To achieve my training and research objectives, I have assembled an exceptional and interdisciplinary team of mentors and collaborators including Dr. Yin Shen (primary mentor, functional genomics and gene regulation), Dr. Arnold Kriegstein (co-mentor, brain organoid), Dr. Katherine Pollard (co-mentor, statistics and machine learning), Dr. Hongjun Song (co-mentor, SCZ neurobiology), and Dr. Xin Jin (collaborator, complex in vivo screening methodologies). This comprehensive mentorship and collaborative research environment will foster my transition to an independent research career, with a long-term goal of elucidating the genomic mechanisms underpinning neurological disorders, ultimately enabling the identification of novel therapeutic targets for prevention and treatment.

Administration for Children & Families - ACYF/FYSB

The Basic Center Program (BCP) provides temporary, emergency shelter; and counseling services to youth who have left home without permission of their parents or guardians, have been forced to leave home, or other homeless youth who might otherwise end up in the law enforcement or in the child welfare, mental health, or juvenile justice systems. BCPs work to establish or strengthen community-based programs that meet the immediate needs of runaway and homeless youth and their families. BCPs provide youth under 18 years of age with food, clothing, counseling and referrals for health care. BCPs can provide up to 21 days of shelter for youth and seeks to reunite young people with their families, whenever possible, or to locate appropriate alternative placements.

Administration for Children & Families - ACYF/FYSB

<p>The Basic Center Program (BCP) provides temporary, emergency shelter; and counseling services to youth who have left home without permission of their parents or guardians, have been forced to leave home, or other homeless youth who might otherwise end up in the law enforcement or in the child welfare, mental health, or juvenile justice systems. BCPs work to establish or strengthen community-based programs that meet the immediate needs of runaway and homeless youth and their families. BCPs provide youth under 18 years of age with food, clothing, counseling and referrals for health care. BCPs can provide up to 21 days of shelter for youth and seeks to reunite young people with their families, whenever possible, or to locate appropriate alternative placements.</p>

Substance Abuse and Mental Health Services Adminis

FY 2026 Congressionally Directed Spending Projects

Substance Abuse and Mental Health Services Adminis

The purpose of this funding opportunity is to provide general information to organizations identified as Congressionally Directed Spending (CDS) Projects in the Consolidated Appropriations Act, 2026. Note: Award amounts for the CDS Projects are included in Appendix A of the NOFO.

Substance Abuse and Mental Health Services Adminis

The purpose of the 988 Tribal response program is to improve connection and response to 988 contacts (including calls, chats, and texts) originating in Tribal communities and/or activated by American Indians/Alaska Natives. American Indian and Alaska Native communities experience a significantly higher suicide risk compared to the general population. CDC reports that in 2022 non-Hispanic Al/AN people had a suicide rate 91% greater than the general population.

Substance Abuse and Mental Health Services Adminis

<p>The purpose of the 988 Tribal response program is to improve connection and response to 988 contacts (including calls, chats, and texts) originating in Tribal communities and/or activated by American Indians/Alaska Natives. American Indian and Alaska Native communities experience a significantly higher suicide risk compared to the general population. CDC reports that in 2022 non-Hispanic Al/AN people had a suicide rate 91% greater than the general population.</p>

Substance Abuse and Mental Health Services Adminis

FY2026 Support for 988 Tribal Response Cooperative Agreements

Community Oriented Policing Services

The Office of Community Oriented Policing Services (COPS) is the component of the U.S. Department of Justice responsible for advancing the practice of community policing and the Administration s priority of Making America Safe Again by supporting the nation s state, local, territorial and Tribal law enforcement agencies through information and grant resources. This is a notice of funding opportunity (NOFO) for the FY26 Law Enforcement Mental Health and Wellness Act (LEMHWA) Program. The mental health and wellness of law enforcement officers and their families is a priority of the Administration. Through the LEMHWA program, the Department of Justice supports this priority by providing funding directly to state, local, tribal, and territorial (SLTT) law enforcement agencies to implement new or enhance existing programs that offer training and services to support officers emotional and mental health including, counseling programs, peer mentoring, suicide prevention, stress reduction, and police officer family services. As community policing is common sense policing, throughout the FY26 LEMHWA program NOFO materials, the terms community policing and common sense policing are used interchangeably, unless otherwise specified. The COPS Office seeks to increase the delivery of and access to mental health and wellness services through this NOFO in the following three funding categories: Category 1: FY26 Start-up LEMHWA Implementation Projects The purpose of this program is to provide funding to law enforcement agencies that do not have established law-enforcement specific mental health and wellness programming. These funds will serve as start-up funding to support the development of new mental health and wellness services and programming for employees of law enforcement agencies and their families. This program also serves to increase grant funding accessibility for small and understaffed departments, especially those in rural communities, to implement mental health and wellness programs. Implementation of peer support, training, family resources, suicide prevention, stress reduction, clinical support, and other promising practices for wellness programs are highly encouraged. Agencies that currently offer rudimentary or limited wellness services and are seeking to develop a comprehensive wellness program for their department are encouraged to apply. Category 2: FY26 Enhanced LEMHWA Implementation Projects The purpose of this program is to provide funding to law enforcement agencies who have current wellness programs in place and are seeking to enhance or expand upon those existing wellness programs. Category 3: FY26 LEMHWA Community of Practice Initiative The purpose of this initiative is to provide support to current and future LEMHWA grantees, that include peer support and technical assistance through the development and facilitation of an innovative forum where grantees can learn from their peers and share promising practices.

Community Oriented Policing Services

FY26 Law Enforcement Mental Health and Wellness Act Program

Community Oriented Policing Services

The Office of Community Oriented Policing Services (COPS) is the component of the U.S. Department of Justice responsible for advancing the practice of community policing and the Administration s priority of Making America Safe Again by supporting the nation s state, local, territorial and Tribal law enforcement agencies through information and grant resources. This is a notice of funding opportunity (NOFO) for the FY26 Preparing for Active Shooter Situations (PASS) Program. The preparedness of law enforcement to respond to active shooter incidents is a priority of the Administration. Through the PASS program, the Department of Justice supports this priority by providing funding to deliver nationally recognized, scenario-based training that prepares officers, first responders, and mental health and social service providers on how best to prepare their communities for an active shooter threat or act of terrorism. PASS program funds are used to increase public and law enforcement safety nationwide by training first responders including law enforcement, fire, emergency medical services (EMS), dispatchers, medical personnel, facility security, emergency management, and any other professionals who may reasonably be key to a successful integrated response to handle an active shooter threat or act of terrorism. In addition, this program will provide priority access to training for School Resource Officers funded under the COPS Hiring Program, to support active shooter preparedness and response in primary and secondary schools. Training provided under the PASS program will advance the goal of the 2016 Protecting Our Lives by Initiating COPS Expansion (POLICE) Act in offering scenario-based, integrated response courses designed to counter active shooter threats or acts of terrorism against individuals or facilities.

Community Oriented Policing Services

The Office of Community Oriented Policing Services (COPS) is the component of the U.S. Department of Justice responsible for advancing the practice of community policing and the Administration’s priority of Making America Safe Again by supporting the nation’s state, local, territorial and Tribal law enforcement agencies through information and grant resources. This is a notice of funding opportunity (NOFO) for the FY26 Preparing for Active Shooter Situations (PASS) Program. The preparedness of law enforcement to respond to active shooter incidents is a priority of the Administration. Through the PASS program, the Department of Justice supports this priority by providing funding to deliver nationally recognized, scenario-based training that prepares officers, first responders, and mental health and social service providers on how best to prepare their communities for an active shooter threat or act of terrorism. PASS program funds are used to increase public and law enforcement safety nationwide by training first responders—including law enforcement, fire, emergency medical services (EMS), dispatchers, medical personnel, facility security, emergency management, and any other professionals who may reasonably be key to a successful integrated response—to handle an active shooter threat or act of terrorism. In addition, this program will provide priority access to training for School Resource Officers funded under the COPS Hiring Program, to support active shooter preparedness and response in primary and secondary schools. Training provided under the PASS program will advance the goal of the 2016 Protecting Our Lives by Initiating COPS Expansion (POLICE) Act in offering scenario-based, integrated response courses designed to counter active shooter threats or acts of terrorism against individuals or facilities.

Substance Abuse and Mental Health Services Adminis

Garrett Lee Smith Campus Suicide Prevention

NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development

PROJECT SUMMARY/ABSTRACT The proposed project for a K23 Career Development Award will enable Dr. Camilia Kamoun to become an independent physician-scientist expert in patient-centered research on psychosocial health in early female puberty. Early female puberty is increasingly common, yet there is a lack of patient-centered tools to assess its psychosocial impact and guide treatment decisions. The proposed research aims to develop a patient-oriented outcomes (PROs) measure for early puberty, addressing a critical gap in evidence-based, patient-centered care. This research would positively impact public health given high rates of early puberty. Dr. Kamoun’s long- term goal is to become an expert in researching psychosocial health in pediatric patients with endocrine conditions, integrating bioethical inquiry to advance just, patient-centered care. Her strong research background, as well as bioethics training, make her an ideal candidate. The research has the following specific aims: 1) To characterize parental health concerns related to early female puberty, as well as parental experiences of its social and mental health impacts; 2) To understand parental prioritization of patient-reported health outcomes for early female puberty and explore their association with parental and child traits; and 3) To assess early female puberty-related PROs using adapted existing relevant PROMIS® measures. These aims will be accomplished through integrated mixed methods. They will lead to the development of a patient- oriented outcomes measure to use in a clinical trial to assess the effect of pubertal suppression treatment on psychosocial health in early female puberty, which will constitute the next steps in the research. In the last two years of the K23, Dr. Kamoun will develop an R01 or equivalent proposal to secure funding for this follow-up research. An interdisciplinary team of mentors and collaborators will guide Dr. Kamoun in accomplishing the following training goals: 1) To acquire advanced theoretical and practical knowledge of research methodologies used in patient-centered research; 2) To gain skills and knowledge in patient-oriented health outcomes research; 3) To acquire knowledge in peripubertal psychoneuroendocrinology and developmental psychology; 4) To deepen her bioethics expertise with a focus on pediatric, research, women’s health ethics, and the relationship between risks, values and ethical care. This training will include survey science coursework through the Odum Institute for Research in Social Science at UNC-CH and advanced bioethics training through the Children's Mercy Bioethics Center's Certificate Program in Pediatric Bioethics. Dr. Kamoun’s mentorship team will meet regularly with her to monitor progress, as well as to provide guidance in writing manuscripts and R01 and equivalent grant proposals. This K23 Career Development Award will provide Dr. Kamoun with the necessary training, mentorship, and research foundation to launch an innovative patient- centered research program that aligns with the Eunice Kennedy Shriver National Institute of Child Health and Human Development’s mission to improve child and adolescent health and the transition to adulthood.

NIMH - National Institute of Mental Health

Dysregulation of basal ganglia and cortical development in the forebrain is central to epilepsy, mental deficiency, autism and schizophrenia. During forebrain development, the medial ganglionic eminence (MGE) generates GABAergic projection neurons in the basal ganglia and GABAergic interneurons in the cortex and hippocampus. We aim to identify transcriptional and epigenetic mechanisms that control cell fate specification and neuronal differentiation of these forebrain GABAergic neurons - information that will lead to insights into how abnormalities in specific gene networks cause human neuropsychiatric disorders.

NIMH - National Institute of Mental Health

Summary One of the major problems in human genetics is understanding the genetic causes underlying complex phenotypes, including neuropsychiatric traits such as autism spectrum disorders, bipolar and schizophrenia. Despite tremendous work over the past few decades, it has been frustratingly difficult to get a good understanding of the underlying biological mechanisms in most cases. Nonetheless, large psychiatric genetic studies are beginning to deliver fundamental knowledge about genetic architecture, disease pathways and specific genetic loci for follow-up. Most psychiatric genetic studies to date have focused on individuals of European origin, leading to profound difference in genetic discoveries with limited transferability of results across populations, but also limiting our knowledge about disease pathophysiology in general. Recently, several large projects in neuropsychiatric genetics have focused on collecting and assembling genetic and deep phenotype data in admixed and populations of different geographic origins. Such projects include the Latin American Genomics Consortium (LAGC), the Genomics of Autism in Latino Ancestries (GALA), the Ancestral Population Network (APN), and PsycheMERGE. Most approaches for causal variant discovery fail to account for key complexities that arise in studies of varying geographic origin, including heterogeneity across populations in terms of effect sizes and linkage disequilibrium (LD) structure, and correlations across geographic origins. Furthermore, with meta-analyses with external LD from reference panels being commonly used in genome-wide association studies, certain types of inconsistencies are inevitable. Therefore, existing methods tend to have suboptimal power and can even produce invalid results, i.e., they prioritize non-causal variants. We propose to develop robust fine-mapping tools that model heterogeneity across populations and are robust to inconsistencies in the data. We also propose to leverage a possibly large number of genetically related traits available in electronic health record systems, including diagnoses, lab results and biomarkers with the goal to refine phenotypes and improve power of genetic association studies for psychiatric phenotypes. We further propose to apply these methods to the largest available collections of datasets from various geographic origins for autism, bipolar, schizophrenia and other neuropsychiatric traits, including data from several psychiatric genetics consortia and electronic health record systems. We believe that the proposed research is very timely and leverages modern datasets with the potential to substantially improve our understanding of the biological mechanisms underlying risk to neuropsychiatric diseases, including schizophrenia, autism and related disorders.

NIMH - National Institute of Mental Health

Although the rate of suicide death across the U.S. has risen dramatically over the past two decades, prevention of mortality remains challenging. This proposal will continue discovery efforts leveraging unique genetic data, comprehensive health records, and deep genealogical records. The variation in responses to environmental and social risks due to underlying genetic vulnerabilities creates an opportunity for discovery of subtypes of individuals at particularly high risk for mortality to lead to future clinical translation. Thus far, genetic discoveries associated with suicidality remain largely removed from translational utility, and are additionally primarily focused on the outcome of suicide attempt. Among individuals with evident suicidality, fewer than 10% go on to die by suicide, and roughly half of suicide deaths occur with no prior evidence of suicide attempts, suggesting that suicide attempt may be a poor proxy for determining risks leading to mortality. Data resources in the Utah Suicide Mortality Risk Study (USMRS) offer much needed opportunities to bridge this knowledge gap, including >12,000 suicide deaths linked to statewide electronic health records; ~9,000 with genotyping, and 1,053 selected for high extended familial risk with whole genome sequencing. All data linkage, subsequent de-identification, and analyses are possible via the Utah Population Database (UPDB); this comprehensive statewide resource also includes unique knowledge of familial risk through genealogical records that go back to the 1700s. In the previous award period, we used the WGS resource, prioritizing genomic regions using 43 very extended families at high risk of suicide death. We pursued non- synonymous variants in the NRXN1 gene which is important for synaptic function, demonstrating the utility of the familial approach. We more broadly characterized suicide deaths with significant extended familiality, finding significant reduction in age at death and significant increase in polygenic risk specific to suicide. We expanded our sequencing sample from N=281 to N=1,053, prioritizing suicide deaths in extended high-risk families. In addition to familial prioritization, we prioritized brain-related expression quantitative trait loci in the deaths with WGS, finding significance associated with RFPL3S (a gene important for arousal), in addition to implicating other gene pathways. We characterized non-transmitted genomic deletions using a conservative strategy of internal replication and rigorous bench validation. Our large sample of genotyped suicides provides information regarding background common genetic risks of hundreds of diagnoses and traits via polygenic scores. Additional ongoing work has also strongly implicated underlying transdiagnostic risks above and beyond psychiatric risks, driving new research directions. We propose to target discovery of mechanistic genomic change within homogeneous subtypes. Extended families provide one method of reducing heterogeneity. We also propose complementary strategies of risk discovery within extreme subtypes of physiological stress response and of brain-related function.

Georgia Veterans Commission

State grants for veteran service programs in Georgia including housing, employment, education, and mental health support.

NIMH - National Institute of Mental Health

PROJECT SUMMARY Serotonin is an important growth factor during gestation. Animal studies have shown that in early gestation, before the fetus’ own ability to synthesize serotonin develops, the mother’s serotonin system plays an important role in the fetus’ brain development in ways that impact future cognition and behavior. In mice, for example, we found that manipulation of the maternal serotonin system alters placental gene expression, fetal brain serotonin levels, and neuronal projections from the thalamus to the somatosensory cortex. When we initially tested these pathways in humans, we saw a similar initial relationship between maternal whole blood serotonin and offspring symptom severity; however, that study was retrospective, and restricted to a clinical population with autism spectrum disorder, and no study has examined the role of the placenta. Recognizing these limitations, it would be premature to develop a large new study without first testing whether and how the pathways identified in the animal models are conserved in humans. Thus, we propose an Exploratory/Developmental R21 project harnassing the strengths of an ongoing study of 375 mother-infants being followed from early pregnancy to offspring 30-36 months of life (R01MH119510). Because the parent study has already collected the maternal blood in early pregnancy, placenta and cordblood, infant neuroimaging at 2-4 weeks of age, and prospective offspring cognitive and behavioral assessments, there is no data collection in this proposal, and we will be able to test our questions immediately and cost-effectively. Our central hypothesis that lower maternal (but not paternal) whole blood serotonin levels in early (14-18 weeks) pregnancy will be associated with changes in placental transcriptome and diminished cord blood serotonin, reduced infant thalamocortical connectivity (using existing structural connectivity measures) at 2-4 weeks of life, and, ultimately, difficulties in neurocognitive and social functioning at 30-36 months of age. Preliminary analyses of the first twenty maternal blood samples we collected support feasibility and demonstrate a range of serotonin levels consistent with those in the population. This developmental proposal will dissect, for the first time, the effects of maternal and placental serotonergic systems on offspring brain and neurodevelopment. Anchoring this proposal to an established study further provides a rigorous and cost-effective infrastructure. Data from this study can fuel future studies to confirm and test generalizability of mechanisms in larger samples, and test promising interventions. Importantly, serotonin function is modifiable, e.g., through diet, micribiome and pharmacological changes, potentially opening up opportunities for maternal screening and prevention.

Give an Hour

Grants for expanding networks of mental health providers offering free services to veterans and military families.

National Institutes of Health

In 1999, at the direction of Congress, the National Institute on Aging (NIA), in conjunction with the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Nursing Research (NINR) embarked on the Alzheimer's Disease (AD) Prevention Initiative. An important part of the AD Prevention Initiative is to quicken the pace for translating basic science findings into clinical trials to evaluate treatment and prevention strategies. This Funding Opportunity Announcement (FOA) focuses on AD drug discovery while companion FOAs are targeted to AD drug development and AD pilot clinical trials. In this FOA, participating institutes invite qualified researchers to submit research grant applications directed toward the discovery, development, and preclinical testing in cellular, tissue, and animal models of novel compounds for the prevention and treatment of the cognitive impairment and behavioral symptoms associated with Alzheimer's disease (AD). Applications submitted to the NIH will be assigned and reviewed according to the usual NIH peer review procedures. Meritorious applications will be funded by the assigned NIH Institutes or co-funded by the assigned NIH Institute and the Institute for the Study of Aging (ISOA). NIA has set-aside $3.0 Million total costs in FY 2006 for applications sent in response to this PA. -This FOA will use the NIH Exploratory/Developmental Grant (R21) award mechanism. -The R21 is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. -All investigator-initiated exploratory/developmental grant applications described in this announcement will be assigned to participating ICs according to standard PHS referral guidelines and specific program interests. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Project Period and Award Levels: The applicant may request a project period of up to two years with a combined budget for direct costs of up to $275,000 for the two-year period. -Eligible organizations: For-profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Eligible agencies of the Federal government; Units of State government; Units of local government; Domestic Institutions; and Foreign Institutions. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge and resources necessary to carry out the proposed research, is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -An R21 is not renewable. -Applicants may submit more than one application, provided they are scientifically distinct.

Substance Abuse and Mental Health Services Adminis

Grants to Expand Substance Use Disorder Treatment Capacity in Adult and Family Treatment Drug Courts

Substance Abuse and Mental Health Services Adminis

The purpose of this program is to expand substance use disorder (SUD) treatment and recovery support services in existing drug courts. Grant recipients will be required to implement a coordinated, multisystem approach that combines the legal authority of treatment drug courts with evidence-based SUD treatment services.IMPORTANT NOTE: SAMHSA will accept and review only the first 50 complete, successfully submitted, and high-quality applications received via eRA. Once this threshold is met, the submission portal will close, and no further applications will be considered.

NHLBI - National Heart Lung and Blood Institute

Project Summary Sudden, life-threatening cardiac events can be terrifying experiences that can trigger the onset of posttraumatic stress disorder (PTSD). PTSD symptoms are common after cardiac events, with over 1 in 5 patients receiving implantable cardioverter defibrillators (ICDs) for prevention of life-threatening arrhythmias and sudden cardiac arrest exhibiting elevated PTSD symptoms. Cardiac disease-induced PTSD symptoms are associated not only with worse mental health but a worse clinical prognosis, including poorer quality of life (QoL), greater disability, and greater risk of event recurrence and/or all-cause mortality. Further, cardiac-focused anxiety sensitivity—a unique aspect of cardiac disease-induced PTSD—is linked to worse health, medical reassurance seeking, and greater healthcare utilization. However, evidence-based interventions for these cardiac-induced psychological presentations are lacking. This R34 proposal will draw from existing, evidence-based psychotherapies to develop a streamlined intervention that addresses cardiac trauma-related fear and cardiac-focused anxiety sensitivity— two key manifestations of PTSD after cardiac events that relate to adverse outcomes and are direct targets of gold standard, exposure-based interventions for PTSD and panic disorder. Trauma-focused exposure reduces trauma-related fear and interoceptive exposure reduces anxiety sensitivity, but neither intervention has been tested in patients with cardiac trauma. After initial intervention development (Stage Ia), a pilot randomized controlled trial (RCT) will be conducted (Stage Ib), in which patients with ICDs (N=70) from the UCLA Cardiac Arrhythmia Center will be randomized to 1) the trauma and anxiety sensitivity exposure-based treatment, called Cardiac Fears Treatment (CFT), or 2) standard supportive therapy (treatment as usual [TAU]). Participants will be assessed at pre-treatment, several periods throughout treatment, post-treatment, and a 6-month follow-up. In Aim 1, we will develop the CFT intervention using an iterative approach, guided by prior research and qualitative interviews with key stakeholders (e.g., cardiology experts), and pilot testing in a small (N=8) open trial of patients with ICDs will yield initial feasibility and acceptability data. Subsequent aims will analyze data from the pilot RCT, generating additional feasibility and acceptability data, along with preliminary efficacy information. In Aim 2, we will compare CFT to TAU on psychological responses (self-report and behavioral task measures of cardiac trauma-related fear and cardiac-focused anxiety sensitivity). Aim 3 will compare CFT to TAU on health- related outcomes (health-related QoL and healthcare utilization). Finally, in Aim 4, we will explore whether key psychological processes targeted in the intervention (cardiac trauma-related fear and cardiac-focused anxiety sensitivity) mediate change in health-related outcomes. By targeting key psychological processes associated with adverse outcomes after a cardiac trauma, this mechanism-focused study has the potential to improve the emotional and physical health of cardiac patients and will generate critical feasibility, acceptability, and preliminary efficacy data needed to inform a grant proposal to test a refined version of CFT in a larger RCT.